ShareCompartir
Volume 14, Number 2—February 2008
Research
Effectiveness of Personal Protective Measures to Prevent Lyme Disease
Marietta Vázquez*
, Catherine Muehlenbein*, Matthew L. Cartter†, Edward B. Hayes‡, Starr Ertel†, and Eugene D. Shapiro*
, Catherine Muehlenbein*, Matthew L. Cartter†, Edward B. Hayes‡, Starr Ertel†, and Eugene D. Shapiro*
Table 2
Characteristics of Lyme disease study participants, Connecticut, July 2000 through February 2003
| Characteristics | Case-patients (N = 709), no. (%) | Controls (N = 1,128), no. (%) | p value |
|---|---|---|---|
| Age, y | |||
| Median | 48 | 49 | 0.71 |
| Mean | 46 | 47 | |
| Range | 15–70 | 15–70 | |
| Sex | |||
| Female | 376 (53) | 715 (63) | <0.001 |
| Male | 333 (47) | 413 (37) | |
| Race | |||
| Caucasian | 689 (97) | 1094 (97) | 0.66 |
| African American | 3 | 8 | |
| Hispanic | 4 | 6 | |
| Other | 13 | 14 | |
| Underlying medical problems other than Lyme disease (e.g., diabetes, asthma) | 298 (42) | 508 (45) | 0.19 |
| Had Lyme disease* | 110 (17) | 143 (14) | 0.095 |
| Received Lyme vaccine† | 44 (6) | 73 (6) | 0.82 |
*Having Lyme disease was defined as the following: for case-patients, having Lyme disease at a time other than the episode for which a case-patient was enrolled in the study; for controls, having Lyme disease at a time other than the focal time of disease for the case-patient.
†A study participant was considered vaccinated if he or she received at least 1 dose of Lyme vaccine.
- Page created: July 08, 2010
- Page last updated: July 08, 2010
- Page last reviewed: July 08, 2010
- Centers for Disease Control and Prevention,
-
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)